FDA Clears Allogeneic CAR-T MT027 for Phase II Glioblastoma
December 21, 2025 | Beijing, China — T-MAXIMUM Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has...
solid tumors
Advertisement
PRAME Cell Therapy Shows Strong Early Responses in Phase 1 Study
HOUSTON, Texas & TÜBINGEN, Germany — December 11, 2025 — Immatics N.V. announced compelling Phase 1a dose-escalation data for...
Rondo Therapeutics Begins Phase I Trial of RNDO-564 in Advanced Tumors
Dateline – San Francisco, CA – December 2025: Rondo Therapeutics has dosed the first patient in its Phase I...
Verismo Therapeutics Unveils Promising CAR T Advances for Solid Tumors at SITC 2025
Philadelphia, November 10, 2025 — Verismo Therapeutics, a clinical-stage biotechnology company pioneering KIR-CAR T cell therapies, presented compelling preclinical...
Abalos Therapeutics’ ABX-001 Validated in Cell Reports Medicine
October 14, 2025 | Düsseldorf, Germany — Abalos Therapeutics announced the publication of preclinical proof-of-concept data in Cell Reports...
Advertisements
MaxCyte Partners with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
ROCKVILLE, Md., Oct. 6, 2025 — MaxCyte, Inc. announced a Strategic Platform License (SPL) agreement with Moonlight Bio to...
Verismo Partners with Miltenyi Biotec to Advance KIR-CAR Clinical Programs
Philadelphia, September 25, 2025 – Verismo Therapeutics, a clinical-stage biotechnology company specializing in KIR-CAR T cell therapies, has announced...
Tezspire Wins CHMP Backing for Chronic Rhinosinusitis in EU
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
Tagworks Advances TGW101 in Phase 1 Trial for Solid Tumors
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
Advertisement
